Recent Updates
Recently added Catalysts
GLUE

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monday, August 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
Price reaction · baseline $4.68 (2024-08-16 close) · clean, no other GLUE news in the window
day 0 close · peak
+3.4%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+67%
120-day peak, hindsight
Typical move
13.3%
average across 9 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
MRT-2359
Phase 2 · Castration-Resistant Prostate Cancer (CRPC)

Full Press Release Details

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study.
ShareAdd on Google
Tags: GLUE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Aug 19, 2024

Biotech snapshot

Cash runway
$621M liquidity · $15M/mo burn
~41 mo
Minimal dilution risk
Lead asset
MRT-2359Phase 2
Castration-Resistant Prostate Cancer (CRPC) →

Catalyst track record

+67%
best trade around GLUE's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for GLUE.

See every catalyst's timing & PoA →